Navigation Links
Cephalon Completes Acquisition of Arana Therapeutics
Date:8/10/2009

U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota.

Cephalon has a growing presence in Europe, the Middle East and Africa. The Cephalon European headquarters and pre-clinical development center are located in Maisons-Alfort, France, just outside of Paris. Key business units are located in England, Ireland, France, Germany, Italy, Spain, the Netherlands for the Benelux countries, and Poland for Eastern and Central European countries. Cephalon Europe markets more than 30 products in four areas: central nervous system, pain, primary care and oncology.

The company's proprietary products in the United States include: NUVIGIL((R)) (armodafinil) Tablets [C-IV], TREANDA((R)) (bendamustine hydrochloride) for Injection, AMRIX((R) ) (cyclobenzaprine hydrochloride extended-release capsules), FENTORA((R)) (fentanyl buccal tablet) [C-II], PROVIGIL((R)) (modafinil) Tablets [C-IV], TRISENOX((R)) (arsenic trioxide) injection, GABITRIL((R)) (tiagabine hydrochloride), and ACTIQ((R)) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available athttp://www.cephalon.com or by calling 1-800-896-5855.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; creation of a new therapeutic focus on inflammatory diseases; interpretation of clinical results; prospects for regulatory approval; manufactur
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... -- Boston Scientific Corporation (NYSE: BSX ) ... $2 billion aggregate principal amount of its senior notes ... offering consists of $850 million of 4.50 percent notes ... due January 2020 and $300 million of 7.375 percent ... use the net proceeds for general corporate purposes, including ...
(Date:12/14/2009)... ThermoFab, a US-based thermoforming company, has completed the delivery of ... sheet metal to a plastic enclosure with a smaller footprint ... ... Shirley, MA (PRWEB) December 14, 2009 -- ThermoFab, a US-based ... Flow Tester – helping Brookfield move from sheet metal to ...
(Date:12/11/2009)... Therapeutics, Inc., a biopharmaceutical company focused on improving ... cardiovascular and muscle disease, today announced the publication ... crucial role in the progression of amyotrophic lateral ... neuromuscular synaptic regeneration in mice. The findings, ... journal Science , reveal miR-206 as a ...
(Date:12/11/2009)... Algeta ASA (OSE: ALGETA), the,cancer ... center in the,US, the Tulane Cancer Center, ... phase III clinical study of Alpharadin in ... cancer,(CRPC) that has metastasized to the skeleton. ... (ALpharadin in SYMptomatic Prostate CAncer) study is ...
Breaking Biology Technology:Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 2Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 3Thermofab Helps Brookfield Engineering Move To A Compact Custom Plastic Enclosure 2miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4
... TUSTIN, Calif., Nov. 29 AMDL, Inc. ... in Shenzhen,Jiangxi and Jilin China, through its ... an international biopharma company and today,announced that ... from the,Chinese Federation of Industry and Commerce ...
... Pfizer Assets, Talent, ANN ARBOR, Mich., Nov. 29 ... the state of Michigan through the 21st Century,Jobs Fund. ... Michigan loan,fund with a low interest rate, is intended ... the region. Job creation is vital for,consideration for approval ...
... RAPIDS, Mich., Nov. 29 The Center for ... first member of the Xceed,Molecular (http://www.xceedmolecular.com ; ... CMM is the first US site to offer ... giving researchers an,important new tool in disease investigation ...
Other Biology Technology:AMDL's Chinese Subsidiary Wins Key Brand Excellence Award for Anti-Aging Treatment 2Ann Arbor SPARK Receives $3.75M from Michigan's Company Formation & Growth Fund 2Ann Arbor SPARK Receives $3.75M from Michigan's Company Formation & Growth Fund 3Center for Molecular Medicine Offers Xceed Ziplex(TM) Services to Research Community 2
(Date:12/14/2009)... The most comprehensive study to date of the ... appendages may provide important clues to how similar regeneration ... the School of Science at Indiana University-Purdue University Indianapolis ... amputated limbs of axolotls, a type of salamander that ... any level of amputation, with the hope that this ...
(Date:12/14/2009)... feature of humans. That,s until examples of tool use came ... of other mammals. Now, a report in the December 14th ... adds an octopus to the growing list of tool users. ... that the researchers call stilt walking. In it, the soft-bodied ... its eight arms rigid, and raises the whole assembly to ...
(Date:12/14/2009)... preventing some of the stresses of open surgery on the ... organ dysfunction. Laparoscopy is a type of surgery in the ... By adding another gas to the carbon dioxide used to ... Medical Center have found they can preserve more normal blood ... (ENO) helped to open blood vessels and keep blood flowing, ...
Breaking Biology News(10 mins):IUPUI researchers tackle protein mechanisms behind limb regeneration 2Tool use in an invertebrate: The coconut-carrying octopus 2Gas improves blood flow and organ status during minimally invasive surgery 2Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 1Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 2Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 3Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 4Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 5Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 6Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 7Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 8Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 9Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 10Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 11Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 12Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 13Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 14Dr James OConnell Named J H Kanter Prize Laureate 54148 1Dr James OConnell Named J H Kanter Prize Laureate 54148 2Dr James OConnell Named J H Kanter Prize Laureate 54148 3German District Court Rules in Smith 26 Nephews Favor in Patent Infringement Case 54146 1German District Court Rules in Smith 26 Nephews Favor in Patent Infringement Case 54146 2German District Court Rules in Smith 26 Nephews Favor in Patent Infringement Case 54146 3
... a violin to produce strong, elegant notes, researchers at ... outside of the body,s killer immune system cells which ... cells in superb infection- and disease-fighting condition. , In ... Immunology , the researchers describe their discovery of seven ...
... The Journal of Experimental Biology are pleased ... of Sydney is the winner of this year,s JEB ... 28th November in The Journal of Experimental Biology ... the contribution of an outstanding young scientist to an ...
... differentiations in the metabolic make-up of the human ... in the open-access journal PLoS Genetics . ... Karsten Suhre, has conducted a genome-wide association study ... in the breakdown of fats. The resulting differences ...
Other Biology News:Wistar scientists find key to keeping killer T cells in prime shape for fighting infection, cancer 2Wistar scientists find key to keeping killer T cells in prime shape for fighting infection, cancer 3French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 3Study identifies genetic variants giving rise to differences in metabolism 2
... Reagent , 2 x 50 ml 10X TBST Wash ... 0.2 ml BL21 glycerol stock , 0.2 ml BLT5403 ... 1010 pfu T7Select Positive Control Lysate , 1010 ... HRP Conjugate , 2 ml T7Select S-protein , ...
...
Carbonate-Bicarbonate Buffer Capsules. For use in coating ELISA plates. Dissolve contents of 1 capsule in 100 ml deionized water to yield 0.05 M carbonate-bicarbonate buffer, pH 9.6....
Immunogen: Synthetic peptide: S(399) P W S E L E F Q F P D D K D P V W E F(418) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: